Melanoma News and Research

Latest Melanoma News and Research

More genetic sites associated with increase in breast cancer risk discovered

Scientists have found five new regions of the genome that increase a woman's risk of developing breast cancer by between six and 16 per cent, according to a study in Nature Genetics today (Sunday)1.

10 May 2010

Majority of Americans concerned about skin cancer but still like tans

When it comes to tanning, dermatologists have long suspected that most people need an attitude adjustment. Now, results of a new survey by the American Academy of Dermatology (Academy) confirmed that the majority of people still idolize the bronzed look of a tan despite wanting to protect themselves from skin cancer.

10 May 2010

Majority of people like suntan but concerned about skin cancer

10 May 2010

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

New research by scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug Herceptin to certain hard-to-treat brain tumors.

10 May 2010

MUHC's Henry C. Witelson Ocular Pathology Laboratory celebrates tenth anniversary

The Burnier International Ocular Pathology Society is holding a Scientific Colloquium in Montreal today to mark the tenth anniversary of the McGill University Health Centre's Henry C. Witelson Ocular Pathology Laboratory. The lab is an internationally reputed centre for the study and treatment of eye diseases and is leading a global network for the sharing of healthcare knowledge and expertise.

7 May 2010

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U®, Blue Light Photodynamic Therapy Illuminator.

7 May 2010

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.

6 May 2010

Vical reports net loss of $8.5 million for first-quarter 2010

Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.

6 May 2010

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

New research by scientists at The University of Texas Health Science Center at Houston (UTHealth) and The University of Texas M. D. Anderson Cancer Center could make it easier for patients to use a family of promising experimental cancer therapeutics known as small interfering RNA (siRNA).

6 May 2010

New study reveals facial skin cancer occurs predominantly on left-side

In a study appearing in the Journal of the American Academy of Dermatology a Saint Louis University doctor found that facial skin cancers were predominantly on the left-side, and especially in men.

6 May 2010

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announced at BIO2010 in Chicago that its proposal to conduct a Phase I clinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma, has been approved in the UK by the Gene Therapy Advisory Committee and by the Medicines and Healthcare products Regulatory Agency Medicines Division.

5 May 2010

UVA exposure at early age does not cause melanoma

Early life exposure to ultraviolet A light does not cause melanoma in a fish model that previously made that connection, scientists from The University of Texas MD Anderson Cancer Center reported today in the online Early Edition of the Proceedings of the National Academy of Sciences.

5 May 2010

Celldex reports net loss of $6.6 million for first-quarter 2010

Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.

4 May 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended March 31, 2010.

4 May 2010

MicroStockProfit.com releases investment report on Vical

MicroStockProfit.com announces an investment report featuring Vical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

Skin cancer rates going down in Alberta: Research group

It appears that people are listening to doctors' orders to protect their skin from the sun. In the largest Canadian study of non-melanoma skin cancer, Andrei Metelitsa, Gordon Jung and their research group have found skin cancer rates in Alberta are going down in men and have levelled off for women. This comes at a time when American scientists say that skin cancer rates are on the rise.

4 May 2010

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™), today announced it signed a collaboration agreement with the John Wayne Cancer Institute (JWCI) at Saint John's Health Center in Santa Monica, California. Under the terms of the agreement, HTG and JWCI (Department of Molecular Oncology, Dave S. B. Hoon, Ph.D., Director) will collaborate to generate a novel mRNA signature that can measure the gene expression differences in melanoma and benign nevi using HTG's qNPA technology in classical surgical pathology samples.

3 May 2010

AVEENO Brand partners with The Skin Cancer Foundation for Road to Healthy Skin Tour program

To coincide with Skin Cancer Awareness Month, the AVEENO Brand announces its third-year partnership with The Skin Cancer Foundation for the Road to Healthy Skin Tour, a program that has been instrumental in educating people nationwide about skin cancer detection and prevention. This year, the Tour will visit over 80 locations through September.

3 May 2010

FDA oks 'vaccine' to treat prostate cancer

Provenge, developed by Dendreon Corporation, is the first approved "treatment that uses a so-called cancer vaccine, a drug that trains the body's own immune system to fight the disease," The New York Times reports.

3 May 2010

Hartford, Salt Lake City and Denver outshine other U.S. cities on skin cancer awareness

At first glance, Hartford, Salt Lake City and Denver might not seem to have much in common. But a new survey by the American Academy of Dermatology (Academy) found these three cities outshine other U.S. cities in heeding dermatologists' advice on preventing and detecting skin cancer.

3 May 2010

Melanoma News and Research

Latest Melanoma News and Research

More genetic sites associated with increase in breast cancer risk discovered

Majority of Americans concerned about skin cancer but still like tans

Majority of people like suntan but concerned about skin cancer

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

MUHC's Henry C. Witelson Ocular Pathology Laboratory celebrates tenth anniversary

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Vical reports net loss of $8.5 million for first-quarter 2010

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

New study reveals facial skin cancer occurs predominantly on left-side

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

UVA exposure at early age does not cause melanoma

Celldex reports net loss of $6.6 million for first-quarter 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

MicroStockProfit.com releases investment report on Vical

Skin cancer rates going down in Alberta: Research group

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

AVEENO Brand partners with The Skin Cancer Foundation for Road to Healthy Skin Tour program

FDA oks 'vaccine' to treat prostate cancer

Hartford, Salt Lake City and Denver outshine other U.S. cities on skin cancer awareness

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Melanoma News and Research

Latest Melanoma News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in